Connection

Co-Authors

This is a "connection" page, showing publications co-authored by FAYE M JOHNSON and JEFFREY N MYERS.
Connection Strength

2.301
  1. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer. 2021 08 15; 127(16):2916-2925.
    View in: PubMed
    Score: 0.203
  2. Characterizing distant metastases and survival in oropharyngeal squamous cell carcinoma. Head Neck. 2021 07; 43(7):2101-2109.
    View in: PubMed
    Score: 0.202
  3. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Lett. 2018 09 01; 431:64-72.
    View in: PubMed
    Score: 0.166
  4. CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res. 2018 02 01; 78(3):781-797.
    View in: PubMed
    Score: 0.161
  5. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget. 2017 Oct 17; 8(49):86369-86383.
    View in: PubMed
    Score: 0.158
  6. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017 04 28; 392:71-82.
    View in: PubMed
    Score: 0.151
  7. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs. 2015 Sep; 26(8):835-42.
    View in: PubMed
    Score: 0.137
  8. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2738-50.
    View in: PubMed
    Score: 0.128
  9. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med. 2013 Aug 27; 11:198.
    View in: PubMed
    Score: 0.120
  10. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. 2013 Oct; 35(10):1454-60.
    View in: PubMed
    Score: 0.112
  11. Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas. Eur J Cancer. 2024 Mar 02; 202:113983.
    View in: PubMed
    Score: 0.062
  12. Revisiting Feeding Tube Utilization in Oropharynx Cancer: 6-Year Prospective Registry Analysis. Otolaryngol Head Neck Surg. 2024 Feb 14.
    View in: PubMed
    Score: 0.062
  13. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.
    View in: PubMed
    Score: 0.058
  14. High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022; 10:936168.
    View in: PubMed
    Score: 0.055
  15. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. 2022 Apr 20.
    View in: PubMed
    Score: 0.054
  16. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
    View in: PubMed
    Score: 0.054
  17. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 11 03; 12(1):6340.
    View in: PubMed
    Score: 0.053
  18. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.051
  19. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
    View in: PubMed
    Score: 0.050
  20. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020 07 01; 26(13):3211-3219.
    View in: PubMed
    Score: 0.047
  21. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight. 2019 Jan 10; 4(1).
    View in: PubMed
    Score: 0.043
  22. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clin Cancer Res. 2017 Nov 01; 23(21):6541-6554.
    View in: PubMed
    Score: 0.039
  23. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol. 2017 09; 72:90-97.
    View in: PubMed
    Score: 0.039
  24. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck. 2017 04; 39(4):633-638.
    View in: PubMed
    Score: 0.038
  25. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins. Clin Cancer Res. 2015 Nov 01; 21(21):4831-44.
    View in: PubMed
    Score: 0.034
  26. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 2008 May 01; 112(9):2088-100.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.